The development and implementation of rapid molecular diagnostics for tuberculosis (TB) drug-susceptibility testing is critical to inform treatment of patients and to prevent the emergence and spread of resistance. Optimal trial planning for existing tests and those in development will be critical to rapidly gather the evidence necessary to inform World Health Organization review and to support potential policy recommendations. The evidence necessary includes an assessment of the performance for TB and resistance detection as well as an assessment of the operational characteristics of these platforms. The performance assessment should include analytical studies to confirm the limit of detection and assay ability to detect mutations conferring resistance across globally representative strains. The analytical evaluation is typically followed by multisite clinical evaluation studies to confirm diagnostic performance in sites and populations of intended use. This paper summarizes the considerations for the design of these analytical and clinical studies.
The rapid and accurate diagnosis of tuberculosis (TB) and determination of drug susceptibility is critical for patient treatment and to prevent the emergence and spread of resistant strains. Globally, in 2017, less than one third of new TB patients received drug-susceptibility testing (DST) for rifampicin (RIF), one of the most important first-line drugs [1] . This leads to the undertreatment of drug-resistant TB (DR-TB), further amplification and transmission of resistance, and associated mortality [2] . Modeled data predict a rising incidence of multidrug-resistant (MDR)-TB, with an increase of 9%-33% in the Philippines, India, and Russia alone [3, 4] . In 2017, only 50% of those diagnosed with RIF-resistant TB in 2017 had second-line DST performed, even when MDR-TB was suspected [1] . The lack of information on second-line drug susceptibility, especially for TB DST target product profile (TPP) priority compounds such as the fluoroquinolones (FQs) [5] , can lead to catastrophic outcomes for patients, an increased burden on health-systems, and the transmission of resistant TB. Without addressing these key issues, the 2030 Sustainable Development Goal of ending the TB epidemic will not be reached.
In view of the limitations of conventional phenotypic methods, the development of rapid molecular diagnostics for TB DST has become a research and development priority [6] . Although the rollout and uptake of novel DR-TB diagnostics such as the Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) has increased the number of TB and DR-TB cases detected and notified [1, 7] , important diagnosis and treatment gaps remain. In particular, there is a pressing need for rapid molecular DSTs that detect resistance to a wider array of drug compounds, including those prioritized in the TPP [5] . Several novel assays have been developed in line with the existing TPP [5] , and some have already demonstrated promising performance for Mycobacterium tuberculosis complex (MTBC) and drug resistance detection in early studies [8] [9] [10] [11] [12] [13] . However, it is rare that studies of these technologies adequately inform World Health Organization (WHO) review and support potential policy recommendations. For example, these studies (1) often fail to include well characterized comparator assays, (2) do not test an adequate selection of resistance mutations in strains of wide geographic variance, (3) do not include adequate sample size to achieve diagnostic accuracy precision targets, or (4) use a sample flow that does not allow for robust comparisons between the index test, reference test, and comparators.
In this article, we define standards for the generation of evidence for TB DST solutions to ensure that analytical and clinical evaluations answer key questions to enable comprehensive technology review. We summarize our recommendations in Table 1. used as an up-front test and include MTBC detection or only as a reflex test to a positive result from MTBC-detection assays. High-throughput DST assays are typically used at central-level reference laboratories, including level-3 referral laboratories or level-2 district hospitals, whereas lower-throughput DST assays may be implemented at level-1 centers.
A few recently developed assays currently on the pathway to WHO approval and aimed for use in centralized laboratories include the Abbott RealTime MTB and MTB RIF/INH assays (Abbott, North Chicago, IL), the Roche COBAS MTB and MTB-RIF/INH assay (Roche Diagnostics, Basel, Switzerland), the Hain FluoroType MTBDR assay (Hain Lifescience GmbH, Nehren, Germany), and the BD MAX MDR-TB assay (Becton Dickinson, Franklin Lakes, NJ) [8] [9] [10] [11] . The Abbott RealTime MTB assay can diagnose MTBC in 94 samples, with positive specimens reflexed to the RIF/INH assay for MDR-TB diagnosis within 10.5 hours [8, 14] . The Roche COBAS MTB assay also uses real-time polymerase chain reaction (PCR) for MTBC detection and can generate results for 96 tests in one 3.5-hour run, with positive specimens reflexed to the RIF/INH assay for MDR-TB diagnosis an additional 3.5 hours later [15] . The Hain FluoroType MTBDR assay relies upon LATE-PCR amplification and light on/lights off chemistry to detect MTBC and isoniazid (INH) and RIF resistance for 94 samples within 4 hours [16] . A new assay capable of FQ and second-line injectable (SLI) resistance detection using this same technology is currently under development [13] . The BD Max MDR-TB assay is another real-time PCR assay that can be run on the BD MAX System to detect MTBC and INH and RIF resistance for 22 sputum samples in 4 hours [11] . Targeted next-generation sequencing assays will also be an option for versatile centralized TB DST in the near-term [17] . One novel test currently in the pipeline for expanded DST in decentralized settings is the Xpert MTB/XDR assay (Cepheid), which can be run on the GeneXpert platform for INH, FQ, and SLI resistance detection [12] . The Molbio Truenat assay (MolBio Diagnostics Pvt Ltd, Goa, India) that enables MTBC and RIF resistance detection was recently approved for use in India and is undergoing trials for WHO review [18] . An overview of additional DST assays in development, or undergoing validation or regulatory approval, is available through FIND's (Foundation for Innovative New Diagnostics) diagnostic pipeline tracker [19] .
These TB DST assays all claim high sensitivity and specificity for resistance detection in TB clinical samples. Many have additional characteristics that are of added value, including polyvalency, ie, detection and differentiation of nontuberculous mycobacteria (NTM) and viruses (eg, human immunodeficiency virus) on the same platform, and/or • Sample size targets should be set with consideration for TPP-defined target performance estimates for each drug to which the assay claims to detect resistance. Ideally, the width of confidence intervals should be ≤5% for specificity estimates and ≤10% for sensitivity estimates.
Reference standard and comparators • Given the need for a comprehensive picture of drug resistance and the resolution of discrepancies, the use of a composite reference standard that combines genotypic sequencing information and phenotypic susceptibility testing results is recommended Downloaded from https://academic.oup.com/jid/article-abstract/220/Supplement_3/S126/5583862 by guest on 13 January 2020 platform connectivity to facilitate results reporting and sharing ( Table 2 ) [5] . Manufacturers should provide data on these additional characteristics whenever possible. Given the recent update to WHO DR-TB treatment guidelines [20] , it is likely that novel assays will soon be developed that also test for resistance to newer drugs (eg, bedaquiline and/or linezolid) once the molecular basis of resistance to these drugs is well defined [21] . Similar study design considerations will apply to these assays.
GENERAL STUDY DESIGN CONSIDERATIONS
Two types of studies should be considered to assess accuracy and reliability of novel assays for DST to support WHO and country policy making processes: (1) analytical studies in laboratory settings to confirm assay limit of detection for MTBC and resistance detection; and (2) clinical evaluation studies to confirm diagnostic performance on clinical samples collected from a consecutive series or random sample of unselected patients requiring evaluation for TB and DR-TB in sites of intended use (Appendix 1: Glossary). Together, these studies can provide representative data on assay and instrument performance for use in TB high-burden countries and utility across different clinical settings and populations (Table 3) . Ease-of-use assessments and other assessments (see Table 1 in the paper 1 by Denkinger et al) are also a requirement but will not be addressed herein.
ANALYTICAL STUDIES
Independent analytical studies will complement and confirm what manufacturers produce for their assay verification. These studies should be conducted in laboratory settings on the design-locked assay to assess MTBC and resistance detection limits, analytical sensitivity and specificity, inclusivity and exclusivity, and heteroresistance detection against a range of well characterized samples.
Limit of Detection
Given that prospective clinical studies suffer from tested patient population variability (over time, in different geographies, or in different catchment areas), analytical studies of limit of detection (LoD) performed on a standardized panel and against well characterized comparator assays can provide an LoD that can be compared across assays. Ideally, LoD testing should be conducted in a validated sputum matrix to gather sufficient data to fit a Probit curve and estimate the LoD with a 95% confidence interval. Given the extensive data available on Xpert MTB/RIF and Ultra, the inclusion of either assay as a direct comparator is • DNA contamination potential (based on information provided by manufacturer) and actual number of events (eg, if apparent, based on series of false-positive index test results after processing of a positive specimen)
• Maintenance and customer support needs, based on issues reported by sites and periodic assessments, as well as recommended service intervals
• Integration with Laboratory Information Systems, remote access for technical support and device monitoring, key performance indicators a Assay operational characteristics may be captured during clinical trials, as part of separate studies, or may be obtained from information provided by manufacturers and taken into consideration when judging the suitability of a new assay or platform for different environments.
Downloaded from https://academic.oup.com/jid/article-abstract/220/Supplement_3/S126/5583862 by guest on 13 January 2020 recommended to enable benchmarking. Results should confirm that the assay LoD for MTBC is equivalent or superior to at least that reported for Xpert MTB/RIF [17] , in line with TPP criteria [5] , although reduced sensitivity may be acceptable if other assay characteristics would substantially improve availability and access [22] . Limit of detection testing against Ultra may be particularly useful for highly sensitive DST assays to inform placement in testing algorithms (eg, use as either an up-front or reflex test). The LoD for DST resistance targets should also be confirmed, because these estimates will likely be different from the estimates for MTBC detection due to the detection of different and multiple gene targets. In this assessment, the testing of the most common resistance mutations (eg, katG 315ACC for INH resistance; rpoB 531TTG for RIF resistance; gyrA 94GGC for FQ resistance; rplC T460C for linezolid resistance; pncA a-11g for pyrazinamide resistance; and rrs A1401G for SLI resistance detection) may be used to establish LoD for resistance testing to some of the first-and second-line compounds detectable by the assay [23] . Line probe assays (LPAs) may be included as comparators for relevant drug compounds. Ideally, the results of this testing should confirm that assay LoD for resistance detection is equivalent or superior to WHO-endorsed comparators.
It should be noted that only genetically and phenotypically well characterized and quantified samples should be used for LoD assessments. In the absence of a WHO international standard, a standardized panel for dynamic range and LoD determination is available from FIND and Zeptometrix [24] . Assay developers should consider using at least 1 drug-sensitive and 1 drug-resistant strain from such a panel for the LoD assessment of DST assays, to increase confidence in the LoD of the assay for both MTBC and resistance detection.
Detection of Resistance-Conferring Mutations
The ability to detect mutations in resistant strains should also be assessed during this analytical study. This is necessary, because no reasonably sized clinical study will be able to achieve a sufficient diversity of strains and resistance-conferring mutations to adequately challenge assay performance. Ideally, assays should be challenged against mutation panels that include high-confidence resistance mutations of notable global prevalence, covering approximately 80%-90% of known resistance mechanisms for any drug. For example, the katG 315ACC and inhA C-15T mutations represent 80.8% of global INH resistance mechanisms, according to recent mutation grading data [23] . Ideally, 3 independent strains from different WHO regions should be tested for each mutation to guarantee high, reproducible DST assay performance for an epidemiologically diverse set of strains with these relevant resistance mutations. It should be noted that this assessment requires testing against strain panels that have been phenotypically characterized with WHO-endorsed assays, including phenotypic DST on solid or liquid media at the recommended critical concentrations [25] , and sequencing to define the genetic basis of resistance. Existing, high-quality WHO strain banks include the FIND TB Strain Bank, with a diversity of genetically and clinically well characterized resistant strains and matched clinical samples [26] , as well as the Institute of Tropical Medicine (Antwerp, Belgium) [27, 28] , which houses a wide range of MTBC isolates.
Inclusivity and Exclusivity
Analytical studies should also assess DST assay inclusivity and exclusivity, testing assay reactivity against a range of MTBC variants (inclusivity) as well as against other organisms Sensitivity estimates from the clinical trial provide the main evidence and are generally supported by the comparative limit of detection assessment. c Specificity estimates may be mainly based on clinical trial data and are generally supported by data on exclusivity testing provided by the assay developer. d Direct head-to-head comparison of assay to comparators will further increase confidence in the sensitivity estimate (eg, including Xpert as a comparator for the detection of paucibacillary TB, due to the large amount of data available for Xpert MTB/RIF). e The main evidence for sensitivity for detection of resistance-conferring mutations will come from phase 1 because the number of patients with resistant TB as well as the variety of mutations will be limited in a clinical study. f Direct head-to-head comparison to comparators (eg, Hain line probe assay) will further increase confidence in the sensitivity estimate for resistance detection.
Downloaded from https://academic.oup.com/jid/article-abstract/220/Supplement_3/S126/5583862 by guest on 13 January 2020 (exclusivity). Although the use of an epidemiologically diverse set of strains during mutation challenge experiments can generate data regarding assay inclusivity, care should be taken to ensure that the assay has been adequately challenged against MTBC variants. It should also be confirmed that the assay identifies all different MTBC members as TB. For exclusivity testing, a range of NTM and Gram-positive and -negative bacteria, especially those present in oral flora and sputum, should be tested [29] . It is recommended that at least 20 clinically relevant NTMs and at least 10 other bacteria should be tested during this assessment with no observed cross-reactions. Such a panel is available through the European Reference Laboratory Network for TB, and another is currently under development to be available via FIND. This testing may be complemented by an in silico assessment of sequence data, looking at the cross-reactivity of assay primer and probes with all known clinically relevant NTM and pathogens. Finally, interference effects of NTM or human deoxyribonucleic acid (DNA) in mixed samples should be evaluated to confirm assay functionality in these cases [5] .
Heteroresistance Detection
Heteroresistance detection should also be assessed in early analytical studies. Replicate mixtures of wild-type and mutant strains or DNA should be tested by the assay within the context of the LoD at set ratios for the most common resistance mutations in each gene region included in the assay [23] . These ratios might be wider or narrower depending on the type of assay tested. For example, a next-generation sequencing technology would likely have a lower threshold for resistance testing, and so a narrower range of mixtures (eg, 0.5%, 1%, 2%, 5%, and 10% mutant:wildtype) may be tested, compared with a real-time assay (eg, 10%, 25%, 50%, 75%, and 90% mutant:wildtype).
CLINICAL EVALUATION STUDIES
After confirming adequate analytical performance, clinical studies should be conducted to evaluate the diagnostic performance of TB DST assays on patient specimens in settings of intended use. The data generated from these studies on assay accuracy can be correlated with early LoD and analytical performance data. Clinical studies will further contribute substantially to ascertainment of diagnostic specificity, support data generated during exclusivity testing, and provide data on operational characteristics to guide policies for use.
Population and Setting
Clinical evaluations should be conducted in diverse settings representative of the TB epidemic in high-burden countries to ensure the study population closely reflects the target population in settings of intended use. Ideally, at least 3 sites from different WHO regions should be selected for these studies. The selection of sites in diverse geographical regions will also ensure that data on operational characteristics are reflective of special issues that may be encountered in different settings. Patient enrollment based upon DR-TB risk factors (eg, previously treated TB patients) can also be an acceptable strategy to enrich for patients with M/XDR-TB in DST studies (additional details on sample size given below).
Reference Standard and Comparators
Given the importance of accuracy estimates in guiding clinical decisions and directing the development of diagnostic algorithms and clinical guidelines, it is imperative that a sound reference standard and informative comparators are incorporated into evaluation studies (Table 4 ). Currently, culture-based DST methods are the best available reference standard for MTBC and resistance detection, but these methods are not always reproducible or accurate, particularly for resistance detection [30, 31] . Although genotypic methods such as sequencing may be considered a reliable method to confirm the presence of mutations detectable by TB DST, not all genetic resistance mechanisms are known for every drug and some mutations might not be associated with resistance.
Given the need for a comprehensive picture of drug resistance and the resolution of discrepancies between the index test and reference standard in diagnostic accuracy studies, the use of a composite reference standard, combining genotypic sequencing information and phenotypic DST results, is highly recommended. The benefit of a composite reference standard is that it helps overcome the limitations of individual reference tests: if a specimen is resistant according to phenotypic DST or has a known resistance-conferring mutation, the specimen is classified as drug-resistant, but if both phenotypic DST and sequencing indicate susceptibility, the specimen is classified as drug-susceptible. Because specificity of both phenotypic DST and sequencing is high, this creates a more robust reference standard and allows for a more comprehensive picture of diagnostic assay performance, as seen in the recent evaluation of the Hain MTBDRplus Version 2 (Hain Lifescience GmbH, Nehren, Germany) and Nipro NTM+MDRTB (Nipro Corporation, Osaka, Japan) LPAs [32] .
The inclusion of WHO-approved tests as comparators in evaluation studies also provides the ability to benchmark and generate stronger evidence for WHO review [33] . In particular, the inclusion of WHO-endorsed LPAs and the Xpert MTB/RIF and/or Ultra assays can benefit both analytical and clinical evaluation studies, because these assays will likely target the same gene targets as the index tests for first-line and, in the case of the second-line Hain MTBDRsl assay (Hain Lifescience GmbH, Nehren, Germany), FQ and SLI resistance detection. Ideally, an evaluation study should assess the diagnostic accuracy of the index test against phenotypic DST, sequencing, and the composite reference standard as well as compare assay diagnostic performance to included comparators.
Sample Size
Sample size is a critical consideration in designing clinical evaluation studies. Sample size should be set to achieve targeted precision for accuracy estimates. Figure 1 shows how the precision of estimates increases as a function of increasing sample size and also demonstrates where increasing precision comes at high cost in terms of the number of patients recruited. For TB DST solutions, these estimates may be based upon TPP performance estimates [5] . Ideally, sensitivity >95% and specificity ≥98% should be achieved compared with sequencing for all drugs included in the assay, in line with minimally acceptable TPP performance characteristics [5] . Furthermore, sensitivity should be >90% for INH, >95% for RIF, and >90% for FQ compared with phenotypic DST, and specificity ≥98% for drug resistance detection for firstand second-line drugs to which the test is able to identify resistance [5] , with selected sample size establishing high confidence in obtained diagnostic performance estimates. Ideally, the width of target confidence intervals should be ≤5% for specificity estimates and ≤10% for sensitivity estimates (Table 5 ). Sample size estimates should also be inflated to account for the number of index and reference test runs expected to yield indeterminate results or errors (eg, <5% according to TPPs). Calculations should also account for the fact that the resistance profiles of enrolled patients will likely vary by site. For example, the anticipated drug resistance profiles of patients enrolled at a DR-TB referral center would vary from those enrolled at a centralized laboratory in a low-TB prevalence setting.
Sample Flow
In designing the clinical evaluation of a TB DST assay, special attention should be paid to sample flow. The index test should be performed on either the raw or processed clinical sample, or both, according to the target starting material for the assay. The reference test and comparator should be performed on the same samples as the index test when possible, to ensure comparability of results. In the case of sputum-based TB DST assays, the index test might be performed twice: once on the direct sample to evaluate assay performance for raw specimens, and once on the cultured isolate along with the reference and comparator methods (Figure 2 ). This double testing provides estimates of , and aminoglycosides (AGs) and capreomycin when compared with genetic sequencing; specificity 98% (blue line) for any anti-tuberculosis (TB) agent for which the test is able to identify resistance when compared against genetic sequencing; sensitivity 95% (green line) for detecting RIF resistance and 90% (red line) for detecting FQ, PZA, INH, and AG resistance compared with phenotypic cultureThe y-axis shows total width of the 95% confidence interval for sensitivity and specificity for a given sample size. The x-axis shows the necessary number of patients with drug-resistant (DR)-TB to achieve a given precision for sensitivity and the number of patients without DR-TB to achieve a given precision for specificity. Confidence intervals were calculated using the Wilson procedure to calculate CIs for a proportion, using a continuity correction [36] . It should be noted that even a 100-patient increase in this study would only be expected to tighten CIs for assay sensitivity for INH resistance detection by 1%. All other CIs would remain the same. study activities conform with sample collection and processing procedures at clinical sites and do not place undue burden on study participants, as may be the case when acquiring multiple specimens (see more detailed discussion of issues relating to this topic in Paper 2).
Key Issues Beyond Accuracy
There is the additional need to monitor and evaluate other aspects of assay performance that must be planned for when designing clinical studies. Data on assay operation should be collected through observed usage and user appraisal questionnaires during clinical trials to ultimately guide policies regarding assay use. Various assay technical and operational performance parameters that should be measured during clinical studies include time-to-result, indeterminate rates, and other factors, which may also be assessed outside a clinical study, are listed in Table 2 . The need for sample referral and data transmission networks should also be noted, particularly for centralized DST solutions. In addition, operators should take special care in monitoring and noting potential cross-contamination issues when incorporating the DST assays into laboratory flow. Finally, there are important considerations for interpreting reference standard and comparator results from a clinical study. Notably, the potential for the different technologies to detect heteroresistance in clinical samples may be a concern, especially for drugs for which resistant subpopulations are commonly observed, such as the FQs [34, 35] , where the frequency of the resistant allele may be below the threshold of detection of different diagnostic assays. These populations may also be grown out either resistant or susceptible by phenotypic DST, which could lead to discordances between phenotypic DST and sequencing if sequencing is only performed on the culture isolate. For this reason, researchers may consider conserving sputum samples to later perform targeted deep sequencing for discordance resolution. This ensures that the most accurate genotypic reference data is obtained for clinical samples, especially when the index test is being performed directly on the clinical sample. For the analysis of MTBC detection, it is important that results are analyzed by smear status and by patient TB history to account for possible false-positive results due to remnant TB in samples and to ensure that clinical data reflect accurate MTBC detection estimates. These considerations are vital to ensure accurate reporting of study results, including key assay performance parameters (detailed discussion of issues relating to this topic is given in Paper 2).
CONCLUSIONS
As novel tests are developed in line with existing TPPs, appropriate evidence generated on their performance and operational characteristics should rapidly follow. This will ensure that policy recommendations can be made, which is the first step to access these tests for TB patients. Studies following the outline provided here are expected to generate high-quality laboratory and clinical data regarding assay performance and operational characteristics and support WHO review and potential recommendation.
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